Business Wire

Global Experts and Practitioners Unite to Improve Ocean Health by Tackling Systemic Challenges in Marine Management

28.6.2022 15:02:00 EEST | Business Wire | Press release

Share

Marine protected areas (MPAs) are key tools for reducing threats to biodiversity, safeguarding marine and coastal habitats, building climate solutions, and supporting human needs through sustainable use. The Convention on Biological Diversity’s Global Biodiversity Framework may include an ambitious target of expanding MPA coverage to 30% by 2030. However, less than 3% of marine protected areas are meeting their objectives in the face of accelerating local and global threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005443/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr. Lizzie McLeod, Global Reefs Lead for The Nature Conservancy (Photo: Mary Kay Inc.)

To tackle this challenge, a team of experts is convening at the United Nations Oceans Conference in June 2022 in Lisbon, Portugal in a side event entitled, “Quality Matters: Enhancing Governance, Effective Management and Resilience of Marine Protected Areas for Multiple Co-benefits.” The event includes speakers from the private sector, local marine science agencies, representatives from non-profit organizations, governments, and intergovernmental organizations. Speakers will share how they are spearheading technological innovation and best practices in marine management and will spotlight valuable tools, increase collaboration, knowledge sharing, and uptake of lessons learned. Dr. Lizzie McLeod, Global Reefs Lead for The Nature Conservancy notes, “Strong partnerships including the private sector, governments, NGOs, researchers, and local communities are essential to improving ocean health. Harnessing lessons learned and best practices globally to improve ocean management is a conservation priority including the co-creation of solutions with key partners.”

Building on this event, the United Nations Environment Programme, The Nature Conservancy, and other conservation partners, with support from Mary Kay Inc., are developing a suite of decision support tools for marine managers that improve marine management, support the sustainable financing of marine protected areas, and guide marine habitat restoration building on best practices around the world. By leveraging scientific innovation and new technologies and global best practices, marine managers are better able to tackle major threats facing marine ecosystems around the world. “MPAs are key to ocean health and sustainable development. But they are not always effective without a range of support. Decision support tools that enable improved MPA design and management, knowledge sharing, and collaboration are needed to give marine stakeholders the support they need to better protect the oceans,” said Ole Vestergard, Programme Officer, United Nations Environment Programme.

"Mary Kay is delighted to support TNC, in collaboration with UNEP and other experts from around the world, in an effort to protect our world's most precious assets: oceans," said Deborah Gibbins, Mary Kay’s Chief Operating Officer. "These organizations are on the frontlines of the fight to preserve our waterways, and we're hopeful that with Mary Kay's support, they'll have the tools and resources needed to ensure our oceans are healthy for generations to come.

As governments refine their conservation targets, it is timely to highlight new innovations and technologies that help countries meet global biodiversity and sustainable development goals. New decision tools and foundational science are needed to enhance the capacity of marine planners and managers to better manage marine habitats in the face of climate change and other threats.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

About the United Nations Environment Programme (UNEP)

UNEP is the leading global voice on the environment. It provides leadership and encourages partnership in caring for the environment by inspiring, informing, and enabling nations and peoples to improve their quality of life without compromising that of future generations.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

Misty Edgecomb
Communications Director, Protect Oceans, Land and Water
The Nature Conservancy
Las Vegas, Nevada (Pacific time zone)
medgecomb@tnc.org, 484-343-3223 cell
pronouns: she/her, Twitter: @mistyedgecomb

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye